拜瑞妥的用法用量

(Rivaroxaban) has the advantages of high safety factor, high bioavailability, no cross-resistance, high compliance, and no need to monitor INR. With further clinical promotion and application, this drug has gradually been considered as the drug of choice for the prevention and treatment of deep venous thrombosis in the lower limbs. Mastering the correct usage and dosage of Xarelto has become an important issue faced by patients. Today we will learn more about the usage and dosage of Xarelto.

1. To prevent venous thrombosis in adult patients undergoing elective hip or knee replacement surgery:

The recommended dose is Xarelto (rivaroxaban) 10 mg orally once daily. If the wound has stopped bleeding, the first dose of medication should be between 6 and 10 hours after surgery. For patients undergoing major hip surgery, the recommended course of treatment is 35 days. For patients undergoing major knee surgery, the recommended course of treatment is 12 days. If a missed dose occurs, patients should take Xarelto immediately and continue taking the dose once daily the next day.

2. Treat DVT (venous thrombosis) and reduce the risk of acute DVT recurrence and PE:

The recommended dose of Xarelto (rivaroxaban) for initial treatment of acute DVT is 15 mg twice daily for the first three weeks, followed by 20 mg once daily for maintenance treatment and to reduce the risk of DVT recurrence and PE.

3. Used in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism:

The recommended dose of Xarelto (rivaroxaban) is 20 mg once a day, which is also the maximum recommended dose. For patients with low body weight and elderly patients (>75 years old), doctors can use 15 mg once a day as appropriate based on the patient's condition.

Things to note about Xarelto are: 1. Patients with liver and renal insufficiency can significantly increase the blood concentration of this product, leading to an increased risk of bleeding. 2. Patients with active bleeding; patients with liver disease who have coagulation abnormalities and clinically relevant bleeding risks; 3. Contraindicated in pregnant and lactating women. 

Because Xarelto (rivaroxaban) has predictable pharmacokinetic and pharmacodynamic characteristics and fewer drug interactions, compared with traditional anticoagulants, it is more effective, does not require constant monitoring, has good safety, and is easy to use. However, the combined use of strong inhibitors of cYP3A4 and P-gp has not been recommended. It must be emphasized that specific patient groups, such as the elderly and patients with renal impairment, should be aware of dosage adjustments.

The above is the usage and dosage of (Rivaroxaban), I hope it can help you!

Recommended related hot articles: /newsDetail/76588.html